6D-a). Thus, to determine whether HDAC6 overexpression has a tumor suppressive effect in vivo, we subcutaneously injected these cells (Hep3B_HDAC6 Clone #1 and Clone #2) into athymic nude mice. At 45 days postinoculation, tumors were detected in animals injected with mock-transfected cells (Hep3B_Mock). In contrast, tumors were observed in animals injected with Hep3B_HDAC6 Clone #1 or Clone #2 cells from 55 days postinoculation (Fig. 6E). Overall, tumor growth was significantly lower in animals injected

with Hep3B_HDAC6 Clone #1 or Clone #2 cells than that of Hep3B_Mock cells (P ≤ 0.05; Fig. selleck chemical 6E), and average tumor volume at sacrifice was much smaller in the Hep3B_HDAC6 group than Hep3B_Mock group (P ≤ 0.05; Supporting Fig. 9). The overexpression of HDAC6 and reduced acetylation status of α-tubulin were then confirmed in tumor tissues of animals treated with Hep3B_HDAC6 Clone #1 or Clone #2 cells (Fig. 6F). Interestingly, it was found that tumor tissues treated with Hep3B_HDAC6, Clone #1 or Clone #2 cells exhibited increased Beclin 1 expression, and it has been well established

Doxorubicin datasheet that Beclin 1 participates during the early stages of autophagy.18 This result implies that HDAC6 mediates autophagic cell death by way of Beclin 1-induction pathway. Recent studies have demonstrated that the induction of Beclin 1 occurs during autophagy in various cell types. However, it has not been determined how Beclin 1 expression is regulated.19 To investigate whether HDAC6 induces Beclin 1 expression during autophagy in liver cancer cells, we examined the endogenous expressions of Beclin 1 and LC3B-II in Hep3B cells stably expressing HDAC6 (Hep3B_HDAC6 Clone #1 or Clone acetylcholine #2 cells). As shown in Fig. 7A, both Hep3B_HDAC6 Clone #1 and Clone #2 cells expressed markedly more Beclin 1 and LC3B-II than Hep3B_Mock cells. This effect of HDAC6 on autophagy was

confirmed by treating Hep3B cells with ceramide, a potent inducer of autophagic cell death. The increased expression of Beclin 1 and LC3B-II conversion were repressed by HDAC6 knockdown in Hep3B_HDAC6 Clone #1 cells (Fig. 7B). Consistently, treatment of 3-MA suppressed Beclin 1 induction and LC3B-II conversion in Hep3B_HDAC6 Clone #1 and Clone #2 cells (Fig. 7C,D). Thus, to explore whether Beclin 1 plays a critical role in HDAC6-mediated autophagy, we performed knockdown of Beclin 1 in Hep3B_HDAC6 Clone #1 and Clone #2 cells. As expected, Beclin 1 knockdown markedly blocked LC3B-II conversion in both Hep3B_HDAC6 Clone #1 and Clone #2 cells (Fig. 7E,F). Overall, these results suggest that HDAC6 exerts its tumor suppressing effect by way of Beclin 1 and LC3-II processing-dependent autophagy in liver cancer cells. Recent investigations have indicated that JNK is activated during autophagy and that this is required for autophagosome formation, although the underlying mechanism has not been determined.